NASDAQ:APTXAptinyx Stock Price, Forecast & News

Aptinyx's stock was trading at $2.43 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, APTX stock has increased by 66.3% and is now trading at $4.04.
View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptinyx in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Aptinyx.

Aptinyx is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020.
View our earnings forecast for Aptinyx.

Aptinyx will be holding an earnings conference call on Thursday, August 13th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Aptinyx Inc (NASDAQ:APTX) posted its earnings results on Thursday, May, 14th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by $0.01. The business earned $0.82 million during the quarter, compared to analysts' expectations of $0.91 million. Aptinyx had a negative return on equity of 47.99% and a negative net margin of 1,540.42%.
View Aptinyx's earnings history.

6 brokerages have issued 1-year price objectives for Aptinyx's shares. Their forecasts range from $7.00 to $15.00. On average, they expect Aptinyx's stock price to reach $9.67 in the next twelve months. This suggests a possible upside of 139.3% from the stock's current price.
View analysts' price targets for Aptinyx.

Media headlines about APTX stock have been trending negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aptinyx earned a daily sentiment score of -2.1 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near term.
View the latest news about Aptinyx.

Aptinyx saw a increase in short interest during the month of February. As of February 15th, there was short interest totaling 246,700 shares, an increase of 24.3% from the January 31st total of 198,500 shares. Based on an average trading volume of 302,100 shares, the short-interest ratio is presently 0.8 days. Currently, 1.2% of the shares of the company are short sold.
View Aptinyx's Short Interest.

Some companies that are related to Aptinyx include Provention Bio (PRVB), Vectura Group (VEGPF), Frequency Therapeutics (FREQ), ZIOPHARM Oncology (ZIOP), Trillium Therapeutics (TRIL), Nkarta (NKTX), Legend Biotech (AMTI), Kadmon (KDMN), Assembly Biosciences (ASMB), Passage Bio (KROS), ImmunoGen (IMGN), Collegium Pharmaceutical (COLL), Akouos (AKUS), Mirum Pharmaceuticals (MIRM) and Tricida (TCDA).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptinyx investors own include Onconova Therapeutics (ONTX), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Opko Health (OPK), Spero Therapeutics (SPRO), Acer Therapeutics (ACER), ADMA Biologics (ADMA), Corbus Pharmaceuticals (CRBP), Kadmon (KDMN) and Matinas BioPharma (MTNB).

(APTX) raised $77 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 5,300,000 shares at $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

Aptinyx trades on the NASDAQ under the ticker symbol "APTX."

Aptinyx's stock is owned by a number of retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.45%), Meridian Wealth Management LLC (0.07%), New York State Common Retirement Fund (0.05%), Leap Investments LP (0.03%) and UBS Group AG (0.02%). Company insiders that own Aptinyx stock include Adam Koppel, Adams Street Partners Llc, Ashish Khanna, Henry O Gosebruch, Norbert G Riedel, Rachel E Sherman, Robert J Hombach and Torsten M Madsen.
View institutional ownership trends for Aptinyx.

APTX stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Meridian Wealth Management LLC, New York State Common Retirement Fund, Leap Investments LP, and UBS Group AG. Company insiders that have bought Aptinyx stock in the last two years include Adam Koppel, Adams Street Partners Llc, Ashish Khanna, Henry O Gosebruch, Norbert G Riedel, Rachel E Sherman, Robert J Hombach, and Torsten M Madsen.
View insider buying and selling activity for Aptinyx.

Shares of APTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of APTX stock can currently be purchased for approximately $4.04.

Aptinyx has a market capitalization of $184.45 million and generates $3.67 million in revenue each year. The company earns $-57,410,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis.

The official website for Aptinyx is www.aptinyx.com.

Aptinyx's mailing address is 909 DAVIS STREET SUITE 600, EVANSTON IL, 60201. The company can be reached via phone at 847-871-0377 or via email at [email protected]